|Title:||What does schizophrenia teach us about antipsychotics?|
|Journal:||Can J Psychiatry|
|Issue:||3 Suppl 2|
|Alternate Journal:||Canadian journal of psychiatry. Revue canadienne de psychiatrie|
|Abstract:||OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment. METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs. RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response. CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.|
Can J Psychiatry. 2015 Mar
60(3 Suppl 2):S14-8.
|Authors Address:||Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario|
Lead, Subspecialty Clinics, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario
Senior Scientist, Campbell Family Mental Health Research Institute, Toronto, Ontario
Faculty, Institute of Medical Science, Toronto, Ontario.
|Appears in Collections:||2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Using Fade OutX